Market Access News | pharmaphorum

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Santhera seeks speedy FDA review of Duchenne drug vamorolone

Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in the US, setting up a possible approval and launch in the latter half of 2023.

News

GSK shelves arthritis blockbuster hope otilimab after lacklu...

GSK has said it will not be able to move ahead with regulatory filings for otilimab as a treatment for rheumatoid arthritis (RA), after it failed to show the desired level of efficacy in tw

News

J&J nabs FDA okay for BCMA bispecific Tecvayli

Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli – adding to the wide range of therapies available for the

News

abstract shapes, bone structure, 3d render, bone

Ipsen faces yet another delay for rare disease drug in US

Less than a week before Ipsen's palovarotene was due to go in front of an FDA advisory committee, the meeting has been called off following a request by the regulator for more data.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AstraZeneca gets first okay for CTLA4 drug tremelimumab

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

News

BMS lines up follow-up indication for cardiomyopathy drug Ca...

Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped to be a future blockbuster and the top prospect in the compan

Santhera seeks speedy FDA review of Duchenne drug vamorolone

GSK shelves arthritis blockbuster hope otilimab after lacklu...

J&J nabs FDA okay for BCMA bispecific Tecvayli

Ipsen faces yet another delay for rare disease drug in US

AstraZeneca gets first okay for CTLA4 drug tremelimumab

BMS lines up follow-up indication for cardiomyopathy drug Ca...

FDA advisors vote no to Capricor's DMD therapy

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks